YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 11 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Stacy R. LindborgChief Medical Officer - Douglas V. FallerInterim Chief Financial Officer - Joshua BlacherEx…
Earnings Call Insights: Imunon, Inc. (IMNN) Q2 2026 MANAGEMENT VIEW * “The second quarter marked another period of focused execution and key validation of both IMNN-001, our lead asset, and our TheraPlas platform.” (President, CEO & Direct…
(RTTNews) - IMUNON, Inc. (IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported its second-quarter 2026 financial results and provided a business update, with investors focusing on continued progre…
Major earnings expected before the bell on Tuesday include: * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) * Energy Transfer LP (ET [https://seekingalpha.com/symbol/ET]) * Merck & Co. (MRK [https://seekingalpha.com/symbol/MRK]) * Cat…
(RTTNews) - IMUNON, Inc. (IMNN), a clinical-stage biotechnology company, announced Tuesday positive preliminary data from the ongoing Phase 2 minimal residual disease (MRD) trial evaluating IMNN-001 in combination with standard-of-care che…
IMUNON (IMNN [https://seekingalpha.com/symbol/IMNN]) announced a transition in its financial leadership. Jeffrey Church has retired from his role as interim CFO, effective July 1, 2026. He is succeeded by seasoned life sciences financial e…
(RTTNews) - This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology. Regulatory m…
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now availabl…
(RTTNews) - IMUNON, Inc. (IMNN), a clinical-stage company, announced that the company has entered into definitive agreements with expected aggregate gross proceeds of $10 million. The transaction agreement includes 250 shares of non-conver…
medical research woman 2 NEW SIZE ©Michael J. Ermarth Imunon Inc. (NASDAQ:IMNN) traded higher in premarket dealings on Thursday after announcing a $10 million financing package that will support the continued development of its lead ovaria…
Major earnings expected before the bell on Tuesday include: * JD.com (JD [https://seekingalpha.com/symbol/JD]) * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * D-Wave Quantum (QBTS [https://seekingalpha.com/symbol/QBTS]) * Lithium…
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE)…
R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer Company to hold conf…
Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today hosted a co…
Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, analysts and those interested in advanc…
Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage compa…
LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00…
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated…
(RTTNews) - Biotech stocks surged in after-hours trading on Wednesday, October 22, led by Ventyx Biosciences, which soared over 88% on positive Phase 2 data. A mix of earnings updates, clinical news, and investor interest lifted several na…
Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025 Program will feature presentations from ovarian cancer thought leaders, Phase 3 study investigators, oncology and statis…
Company seeks strategic partners to advance novel PlaCCine technology LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies…
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on track with established plans to accelerate…
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial of IMNN-001 underway, with four trial…
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with…
LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company wil…
(RTTNews) - IMUNON, Inc. (IMNN), a clinical-stage biotechnology company, announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring uninterrupted trading on The Nasdaq Capital Market. The confirmation came f…
* IMUNON (NASDAQ:IMNN [https://seekingalpha.com/symbol/IMNN]) on Thursday said it has regained compliance with the minimum bid price requirement for continued listing on Nasdaq. * As a result, IMUNON common stock will continue uninterrupte…
Imunon, Inc. LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance wi…
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimu…
Earnings Call Insights: Imunon, Inc. (IMNN) Q2 2025 MANAGEMENT VIEW * Stacy R. Lindborg, President and CEO, reported unprecedented improvement in overall survival for ovarian cancer patients treated with IMNN-001, stating "Patients in the…
IMUNON INC (NASDAQ:IMNN [https://www.chartmill.com/stock/quote/IMNN]) reported its second-quarter 2025 financial results, revealing a mixed reaction from the market despite beating analyst expectations on earnings per share (EPS). The comp…
Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly dia…
Major earnings expected before the bell on Tuesday include: * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) * Caterpillar (CAT [https://seekingalpha.com/symbol/CAT]) * BP p.l.c. (BP [https://seekingalpha.com/symbol/BP]) * Organon & Co…
* Imunon (NASDAQ:IMNN [https://seekingalpha.com/symbol/IMNN]) is scheduled to announce Q2 earnings results on Tuesday, August 5th, before market open. * The consensus EPS Estimate is -$4.99 [https://seekingalpha.com/symbol/IMNN/earnings/es…
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 deve…
LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m…